SCHEMBL3658616

SCHEMBL3658616

O=C(c1ccc(Cl)c(Cl)c1)c1cc(Cl)ncn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.50
TSHR P16473 1/20 0.47
KMO O15229 3/20 0.45
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
KCNQ3 O43525 1/20 0.43
KCNQ2 O43526 1/20 0.43
KCNE1 P15382 1/20 0.43
KCNQ1 P51787 1/20 0.43
HPGD P15428 1/20 0.42
IGFBP3 P17936 1/20 0.42
GRM4 Q14833 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PKM P14618 2/20 0.40
RORB Q92753 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653195 0.81 SMN1; SMN2 (0.47) TSHRKMONPC1RAB9AKCNQ3
SCHEMBL28242027 0.80 KMO (0.40) KMOGRM4MEN1KMT2ALMNA
SCHEMBL3655141 0.79 KMT2A (0.50) SRD5A2KMONPC1RAB9AHPGD
SCHEMBL3655104 0.78 JAK2 (0.33) KMONPC1RAB9AKMT2AMAPT
SCHEMBL10172455 0.76 HPGD (0.54) NPC1RAB9AHPGDMEN1KMT2A
SCHEMBL3659020 0.76 KMT2A (0.44) NPC1MEN1KMT2AMAPTLMNA
SCHEMBL6322177 0.75 SRD5A2 (0.79) SRD5A2TSHRKMONPC1RAB9A
SCHEMBL3657540 0.74 SMN1; SMN2 (0.55) TSHRRAB9AHPGDMEN1KMT2A
SCHEMBL6525636 0.73 KMO (0.36) KMOKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL3836387 0.73 KMT2A (0.61) SRD5A2TSHRNPC1RAB9AGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205590-B1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-06-04 EP disclosed
US-8629137-B2 CGRP antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-14 US disclosed
US-8629137-B2 CGRP antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-14 US disclosed
US-8629137-B2 CGRP antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-14 US disclosed
US-20130029975-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029975-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20110059954-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-10 US disclosed
US-20110059954-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-10 US disclosed
US-20110059954-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-10 US disclosed
EP-2205590-A1 CGRP ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2010-07-14 EP disclosed
WO-2009050232-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059954-A1 CGRP ANTAGONISTS CALCRL, CALCR, CALCA SRD5A2 1964/4885TSHR 471/4885KMO 3154/4885
US-20130029975-A1 CGRP ANTAGONISTS CALCRL, CALCR, CALCA SRD5A2 1964/4885TSHR 471/4885KMO 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.